Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B

doi:10.4254/wjh.v18.i2.114346

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

This Article

(35)

(38)

(0)

(10)

(1)

(1133)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Feb 27, 2026; 18(2): 114346
Published online Feb 27, 2026. doi: 10.4254/wjh.v18.i2.114346

Table 2 Comparison of 48-week clinical data, n (%)/median (interquartile range)/mean ± SD

Variables	Total (n = 144)	ETV (n = 96)	TMF (n = 48)	P value
HBV DNA undetectable	104 (72.20)	71 (73.96)	33 (68.75)	0.511
HBsAg (log₁₀IU/mL)	3.36 (2.99-3.75)	3.36 (2.97-3.67)	3.37 (3.02-3.89)	0.553
HBeAg positive	58 (40.28)	38 (39.58)	20 (41.67)	0.810
TBIL (μmol/L)	12.9 (9.9-16.9)	13.1 (10.1-17.3)	12.4 (9.5-16.3)	0.499
Alb (g/L)	45.41 ± 2.75	45.44 ± 2.87	45.35 ± 2.51	0.851
ALT (U/L)	24.3 (17.1-33.7)	23.3 (16.8-32.5)	26.3 (17.7-42.5)	0.255
AST (U/L)	23.3 (19.3-30.8)	23.8 (19.3-30.6)	22.7 (19.1-32.3)	0.961
GGT (U/L)	21.2 (14.6-34.0)	21.0 (14.2-28.8)	23.3 (15.0-35.8)	0.454
ALP (U/L)	77.45 ± 22.52	75.04 ± 20.90	82.28 ± 24.97	0.069
TG (mmol/L)	1.22 (0.89-1.65)	1.14 (0.87-1.45)	1.38 (0.90-1.91)	0.092
TC (mmol/L)	4.54 (3.97-4.91)	4.39 (3.86-4.91)	4.62 (4.32-4.91)	0.069
FBG (mmol/L)	5.02 (4.65-5.36)	4.98 (4.63-5.46)	5.10 (4.77-5.32)	0.564
SCr (μmol/L)	70.03 ± 13.15	71.17 ± 13.87	67.76 ± 11.36	0.142
Decline in eGFR (mL/minute/1.73 m²)	4.32 ± 8.60	5.73 ± 9.32	1.49 ± 6.09	0.001
eGFR (mL/minute/1.73 m²)	107.74 ± 11.91	106.10 ± 12.27	111.01 ± 10.53	0.019
BUN (mmol/L)	4.48 ± 1.11	4.41 ± 1.14	4.64 ± 1.06	0.236
HGB (g/L)	148 (135-158)	147 (135-158)	148 (137-158)	0.948
PLT (× 10⁹/L)	198 ± 58	198 ± 61	198 ± 52	0.963
LSM (kPa)	6.8 (5.5-8.2)	6.8 (5.4-8.5)	6.8 (5.5-7.8)	0.541
Liver cirrhosis	16 (11.11)	12 (12.50)	4 (8.33)	0.453

HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; TBIL: Total bilirubin; Alb: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; TG: Triglyceride; TC: Total cholesterol; FBG: Fasting blood glucose; SCr: Serum creatinine; eGFR: Estimated glomerular filtration rate; BUN: Blood urea nitrogen; HGB: Hemoglobin; PLT: Platelet; LSM: Liver stiffness measurement; ETV: Entecavir; TMF: Tenofovir amibufenamide.

Full Size Table

Citation: Ma SP, Wang L, Zhang YL, Wan X, Liu Q, Tang YL, Malhi LR, Ge SF. Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B. World J Hepatol 2026; 18(2): 114346
URL: https://www.wjgnet.com/1948-5182/full/v18/i2/114346.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i2.114346

Ma SP, Wang L, Zhang YL, Wan X, Liu Q, Tang YL, Malhi LR, Ge SF. Effects of tenofovir amibufenamide and entecavir on estimated glomerular filtration rate in treatment-naïve patients with chronic hepatitis B. World J Hepatol 2026; 18(2): 114346 [PMID: 41809484 DOI: 10.4254/wjh.v18.i2.114346]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.